Puma Biotechnology Announces Publication of Abstracts on Neratinib for the 2022 ASCO Annual Meeting
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
- Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the publication of two abstracts on neratinib to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting.
- The ASCO Annual Meeting will be held in person at McCormick Place in Chicago, Illinois, and online from June 3 - 7, 2022.
- The corresponding abstracts of the two posters that Puma will be presenting are now live on the 2022 ASCO Annual Meeting website.
- Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357.